Nicoline Løkken1, Alfred Peter Born2, Morten Duno3, John Vissing1. 1. Copenhagen Neuromuscular Center, section 3342, Righospitalet, Blegdamsvej 9, DK-2100, Copenhagen, Denmark. 2. Department of Pediatrics, Rigshospitalet, University of Copenhagen, Denmark. 3. Department of Clinical Genetics, Rigshospitalet, University of Copenhagen, Denmark.
Abstract
INTRODUCTION: Muscular dystrophy caused by LAMA2-gene mutations is an autosomal recessive disease typically presenting as a severe, early-onset congenital muscular dystrophy (CMD). However, milder cases with a limb-girdle type muscular dystrophy (LGMD) have been described. METHODS: In this study, we assessed the frequency and phenotypic spectrum of LAMA2-related muscular dystrophy in CMD (n = 18) and LGMD2 (n = 128) cohorts identified in the last 15 years in eastern Denmark. The medical history, brain-MRI, muscle pathology, muscle laminin-α2 expression, and genetic analyses were assessed. RESULTS: Molecular genetics revealed 2 pathogenic LAMA2 mutations in 5 of 18 CMD and 3 of 128 LGMD patients, corresponding to a LAMA2-mutation frequency of 28% in the CMD and 2.3% in the LGMD cohorts, respectively. CONCLUSIONS: This study demonstrates a wide clinical spectrum of LAMA2-related muscular dystrophy and its prevalence in an LGMD2 cohort, which indicates that LAMA2 muscular dystrophy should be included in the LGMD2 nomenclature.
INTRODUCTION:Muscular dystrophy caused by LAMA2-gene mutations is an autosomal recessive disease typically presenting as a severe, early-onset congenital muscular dystrophy (CMD). However, milder cases with a limb-girdle type muscular dystrophy (LGMD) have been described. METHODS: In this study, we assessed the frequency and phenotypic spectrum of LAMA2-related muscular dystrophy in CMD (n = 18) and LGMD2 (n = 128) cohorts identified in the last 15 years in eastern Denmark. The medical history, brain-MRI, muscle pathology, muscle laminin-α2 expression, and genetic analyses were assessed. RESULTS: Molecular genetics revealed 2 pathogenic LAMA2 mutations in 5 of 18 CMD and 3 of 128 LGMD patients, corresponding to a LAMA2-mutation frequency of 28% in the CMD and 2.3% in the LGMD cohorts, respectively. CONCLUSIONS: This study demonstrates a wide clinical spectrum of LAMA2-related muscular dystrophy and its prevalence in an LGMD2 cohort, which indicates that LAMA2muscular dystrophy should be included in the LGMD2 nomenclature.
Authors: Hemakumar M Reddy; Kyung-Ah Cho; Monkol Lek; Elicia Estrella; Elise Valkanas; Michael D Jones; Satomi Mitsuhashi; Basil T Darras; Anthony A Amato; Hart Gw Lidov; Catherine A Brownstein; David M Margulies; Timothy W Yu; Mustafa A Salih; Louis M Kunkel; Daniel G MacArthur; Peter B Kang Journal: J Hum Genet Date: 2016-10-06 Impact factor: 3.172
Authors: Christine C Bruels; Hannah R Littel; Audrey L Daugherty; Seth Stafki; Elicia A Estrella; Emily S McGaughy; Don Truong; Jonathan P Badalamenti; Lynn Pais; Vijay S Ganesh; Anne O'Donnell-Luria; Heather J Stalker; Yang Wang; Christin Collins; Andrea Behlmann; Richard J L F Lemmers; Silvère M van der Maarel; Regina Laine; Partha S Ghosh; Basil T Darras; Carla D Zingariello; Christina A Pacak; Louis M Kunkel; Peter B Kang Journal: Ann Clin Transl Neurol Date: 2022-06-23 Impact factor: 5.430
Authors: Alberto A Zambon; Deborah Ridout; Marion Main; Rachael Mein; Rahul Phadke; Francesco Muntoni; Anna Sarkozy Journal: Ann Clin Transl Neurol Date: 2020-09-10 Impact factor: 4.511